
Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. In the first part of the year before we invested, Abbott slightly missed earnings estimates while it was digesting its acquisition of Exact Sciences, along with a variety of turmoil in the medtech and infant nutrition industries. Digital and print publisher People Inc. was a detractor in the quarter, while hospitality and entertainment company MGM Resorts also detracted.










